Beam Therapeutics Inc. Stockholders Equity

Quick Answer

Beam Therapeutics Inc. reported Stockholders Equity of $1.24 billion for fiscal year 2025.

Beam Therapeutics Inc. Stockholders Equity — Annual History

Fiscal Year Stockholders Equity YoY Change
2025 $1.24B +68.8%
2024 $733.54M -25.2%
2023 $981.33M +33.8%
2022 $733.47M -11.3%
2021 $826.74M +236.7%
2020 $245.56M +222.1%
2019 -$201.10M -71.3%
2018 -$117.41M

Quarterly Stockholders Equity

Quarter Ending Stockholders Equity YoY QoQ
September 30, 2025 $966.00M +22.1% -7.7%
June 30, 2025 $1.05B +22.6% -6.8%
March 31, 2025 $1.12B +23.0% +53.1%
December 31, 2024 $733.54M -25.2% -7.3%
September 30, 2024 $791.32M +1.6% -7.4%
June 30, 2024 $854.09M +5.2% -6.5%
March 31, 2024 $913.49M +20.0% -6.9%
December 31, 2023 $981.33M +33.8% +26.0%
  • Beam Therapeutics Inc. showed an increase of +68.8% in Stockholders Equity compared to the prior fiscal year.
  • Over the 2018–2025 period, Beam Therapeutics Inc.’s stockholders equity has grown by 1154.8% (from -$117.41 million to $1.24 billion).
  • The most recent figure is from Beam Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment